Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01541553 · ClinicalTrials.gov registry record · Phase 3
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
NCT01541553 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 367 participants.
The verdict
NCT01541553, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare the rate of complete clearance of actinic keratosis (AK) using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy alone.
Interventions
- DRUG Vehicle
- PROCEDURE Cryotherapy
- DRUG Ingenol metabute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01541553
The ClinicalTrials.gov registry entry for NCT01541553 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT01541553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01541553 about?
NCT01541553 is a clinical study titled "A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp". The purpose of this trial is to compare the rate of complete clearance of actinic keratosis (AK) using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy alone.
What is the current status of trial NCT01541553?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2012-03. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01541553?
The interventions under investigation include: Vehicle (DRUG), Cryotherapy (PROCEDURE), Ingenol metabute (DRUG).
Who is sponsoring clinical trial NCT01541553?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.